{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T02:05:37Z","timestamp":1740103537266,"version":"3.37.3"},"reference-count":34,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2002,10,24]],"date-time":"2002-10-24T00:00:00Z","timestamp":1035417600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100008730","name":"Norwegian Cancer Society","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100008730","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intl Journal of Cancer"],"published-print":{"date-parts":[[2003,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Our study evaluates the prognostic significance of the cytokeratin\u2010positive mononuclear cells (CK+ cells) in the bone marrow (BM) and peripheral blood (PB) as detected by immunocytochemistry in patients with locoregionally confined prostate cancer. BM and PB samples were obtained from 66 newly diagnosed patients with T1\u20104pN0M0 prostate cancer. All samples were analyzed by standardized immunocytochemical methods (anticytokeratin mononuclear antibody; AE1\/AE3) applying a negative immunomagnetic cell enrichment technique. A second sampling was obtained in 60 of the 66 patients \u22652 years after definitive radiotherapy. The median follow\u2010up after high\u2010dose radiotherapy of the patients was 65 months. For the analysis of the postradiotherapy clinical progression\u2010free survival (PFS) treatment, failure was defined as pelvic tumor growth or development of distant metastases. At diagnosis CK+ cells were found in BM in 14 of 66 (21%) prostate cancer patients. This was not associated with an increased risk of progression. On the other hand, the presence of CK+ cells in 12 of 60 (20%) patients at the second BM aspiration was significantly related to a shorterPFS (<jats:italic>p<\/jats:italic> = 0.02). In the multivariate analysis, the presence of CK+ cells in the posttreatment BM did not remain as an independent variable of PFS assessment if posttreatment PSA was entered into the analysis. CK+ cells in PB were found in 12% of the patients. After therapy, none of the patients had detectable CK+ cells in PB. The presence of CK+ cells in the posttreatment but not in the pretreatment BM was associated with decreased PFS in patients irradiated for pelvis\u2010confined nonmetastatic prostate cancer. Although this association was not retained in multivariate analysis, our observations indicate that the presence of CK+ cells after local therapy define a group of patients that have a high risk of developing distant metastases. \u00a9 2002 Wiley\u2010Liss, Inc.<\/jats:p>","DOI":"10.1002\/ijc.10780","type":"journal-article","created":{"date-parts":[[2002,12,19]],"date-time":"2002-12-19T13:59:09Z","timestamp":1040306349000},"page":"91-96","source":"Crossref","is-referenced-by-count":10,"title":["The prognostic impact of cytokeratin\u2010positive cells in bone marrow of patients with localized prostate cancer"],"prefix":"10.1002","volume":"103","author":[{"given":"Wolfgang","family":"Lilleby","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jahn M.","family":"Nesland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophie D.","family":"Foss\u00e5","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Goran","family":"Torlakovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H\u00e5kon","family":"Waehre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gunnar","family":"Kvalheim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2002,11,26]]},"reference":[{"key":"e_1_2_6_2_2","first-page":"152","article-title":"Survival advantage for prostate cancer patients treated with high\u2010dose three\u2010dimensional conformal radiotherapy","volume":"5","author":"Hanks GE","year":"1999","journal-title":"Cancer J Sci Am"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.14.2740"},{"key":"e_1_2_6_4_2","first-page":"70","article-title":"A comparison of prostate cancer treatments: are therapeutic implications justified?","volume":"3","author":"Scardino PT","year":"1997","journal-title":"Cancer J Sci Am"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1997.03540420041027"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1006106209527"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02743464"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1006216504892"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1089\/scd.1.1996.5.359"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02906127"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0093-7754(01)90116-2"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(20010701)92:1<46::AID-CNCR1290>3.0.CO;2-6"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200008243430811"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.5.1788"},{"key":"e_1_2_6_15_2","first-page":"317","article-title":"[Monoclonal antibodies in colorectal carcinoma]","volume":"40","author":"Schlimok G","year":"1999","journal-title":"Internist (Berl)"},{"key":"e_1_2_6_16_2","first-page":"2119","article-title":"Effect of neoadjuvant androgen deprivation on circulating prostate cells in the bone marrow of men undergoing radical prostatectomy","volume":"4","author":"Wood DP","year":"1998","journal-title":"Clin Cancer Res"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)66046-6"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(20010715)92:2<311::AID-CNCR1324>3.0.CO;2-H"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0360-3016(98)00475-1"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0215(19981123)78:5<556::AID-IJC5>3.0.CO;2-G"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-9896(199808)185:4<427::AID-PATH127>3.0.CO;2-7"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1006\/scbi.2001.0388"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(01)63530-4"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.12.3451"},{"key":"e_1_2_6_25_2","first-page":"4122","article-title":"Detection of isolated tumor cells in bone marrow in early\u2010stage breast carcinoma patients: comparison with preoperative clinical parameters and primary tumor characteristics","volume":"7","author":"Naume B","year":"2001","journal-title":"Clin Cancer Res"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1159\/000061332"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1464-410X.1997.d01-6840.x"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1159\/000474553"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0360-3016(99)00089-9"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0045(19981101)37:3<195::AID-PROS10>3.0.CO;2-C"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1097\/00130404-200201000-00011"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.281.17.1591"},{"key":"e_1_2_6_33_2","first-page":"1035","article-title":"Consensus statement: guidelines for PSA following radiation therapy","volume":"37","author":"American Society for Therapeutic Radiology and Oncology Consensus Panel","year":"1997","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0360-3016(02)02707-4"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0045(19990701)40:2<125::AID-PROS8>3.0.CO;2-Y"}],"container-title":["International Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fijc.10780","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ijc.10780","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T17:45:12Z","timestamp":1697219112000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ijc.10780"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,11,26]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2003,1]]}},"alternative-id":["10.1002\/ijc.10780"],"URL":"https:\/\/doi.org\/10.1002\/ijc.10780","archive":["Portico"],"relation":{},"ISSN":["0020-7136","1097-0215"],"issn-type":[{"type":"print","value":"0020-7136"},{"type":"electronic","value":"1097-0215"}],"subject":[],"published":{"date-parts":[[2002,11,26]]}}}